Anne Marie Morse, DO, discusses the promising yet nuanced role of wearable sleep technologies in the evolving landscape of health and wellness. She highlights a generational shift—particularly among Gen Z—toward embracing sleep as a pillar of overall well-being, with wearables empowering users by providing personalized insights into their sleep, heart rate, and oxygenation.
Advertisement
The protective effect of dog exposure early in life was seen in both cohort groups.
Use of SGLT2i with RAASi is associated with reduced risk for hyperkalemia in the clinical setting, a study found.
The SURPASS ET trial evaluated efficacy and safety of ropeginterferon alfa-2b in second-line ET treatment.
The low-FODMAP diet demonstrated superior reduction in IBS-SSS, but the Mediterranean diet also provided relief.
Kidney Care Partners visited called on Congress to support policies benefitting Americans with kidney disease.
AstraZeneca and Aptar Digital Health are partnering on screening algorithms to detect CKD and other conditions.
New drugs like vepdegestrant and oral SERDs may reshape HR+ breast cancer treatment with novel mechanisms and CDK4/6 combos.
Data were presented at EHA2025 on the novel anti-CD38 monoclonal antibody CM313 for chronic ITP.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
The Latest From Heme Today
The SURPASS ET trial evaluated efficacy and safety of ropeginterferon alfa-2b in second-line ET treatment.
Data were presented at EHA2025 on the novel anti-CD38 monoclonal antibody CM313 for chronic ITP.
Evidence was presented at EHA2025 that the agent improves RBC health and blood flow in patients.
Two cases of patients with SCD and history of delayed hemolytic transfusion reaction were presented at EHA2025.
The analysis was an assessment of 15-year follow-up data from the CLIMB study and was presented at EHA2025.
The study data presented at EHA2025 were from patients who had disease resistant to prior therapy or intolerance to therapy.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.